Eye On The Prize: For $8.7 Billion, Valeant Will Acquire Bausch & Lomb
This article was originally published in The Pink Sheet Daily
Executive Summary
As with its Medicis buyout in 2012, Valeant is acquiring another company to serve essentially as a therapeutic division within the specialty pharma the Canadian firm is cobbling together from relentless M&A activity. Buying B&L will increase Valeant’s eye care holdings substantially.
You may also be interested in...
Deals Of The Week: Keeping Score – Valeant Wants Actavis, Which Covets Warner Chilcott …
Meanwhile, companies like Mylan and Novartis also reportedly have joined the Actavis chase. In addition, there’s been deal-making news from Elan and Theravance, Merck-Serono and Quintiles, and AbbVie and Alvine.
Valeant Continues Buying Spree With $2.6B Acquisition Of Medicis
The specialty pharma adds to its dermatology portfolio with a proposed acquisition of Scottsdale, Ariz.-based Medicis.
Valeant Adds Eyetech’s Macugen To Ophthalmic Portfolio
The acquisitive Canadian specialty pharma’s latest deal is a relatively small one, giving it a wet AMD treatment that lags behind Lucentis and other newcomers.